Pre-registration is required, to a maximum of 150 people. No walk-ins will be permitted once maximum is reached.

Contemporary Strategies in the management of invasive aspergillosis in hematologic malignancy patients

Date: Friday, May 4, 2018
Location: Junior Ballroom CD
Sheraton Vancouver Wall Centre
Time: 7:00 - 8:45 am
(Registration and Breakfast 7:00 – 7:20 am)

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Merck Canada Inc. and was planned to achieve scientific integrity, objectivity and balance.

Under the guidance of the Innovative Medicines Canada Code of Ethical Practices, this event is for healthcare professionals only.

Chair / Moderator:
Coleman Rotstein
MD, FRCPC, FACP, FIDSA
Professor of Medicine
Division of Infectious Diseases
Co-Director, Immunocompromised Host Infectious Diseases
Director Oncologic Infectious Diseases
University of Toronto
University Health Network
Toronto, ON

Speakers:

Alissa Jade Wright
MD, FRCPC, MSc
Clinical Assistant Professor
Director, Transplant Infectious Disease Program
Division of Infectious Diseases
University of British Columbia
Vancouver, BC

Donald C. Vinh
MD, FRCPC, FACP
Lilian Wilkins Associate Professor
FRQS Clinician-Scientist
Department of Medicine Division of Infectious Diseases; Division of Allergy & Clinical Immunology
McGill University Health Centre
Montreal, QC

Shariq Haider
MD, FRCPC, FACP, CCST (UK)
Professor Medicine
Division of Infectious Diseases
Department of Medicine
Head Transplant/Malignant Infectious Diseases
Juravinski Hospital and Cancer Centre
McMaster University
Hamilton, ON

Objectives

1. Recognize the burden of illness in Canada, risk factors for and complications of invasive aspergillosis in the affected population.

2. Discuss current and novel diagnostic methods for invasive aspergillosis infections.

3. Outline optimal treatment strategies for the management of invasive aspergillosis in high risk individuals within the context of current treatment guidelines.

This program is supported by an educational grant from

Merck
AMMI Canada
CACMID